Literature DB >> 28561206

4H Leukodystrophy: A Brain Magnetic Resonance Imaging Scoring System.

Suzanne Vrij-van den Bos1, Janna A Hol1, Roberta La Piana2,3, Inga Harting4, Adeline Vanderver5, Frederik Barkhof6,7, Ferdy Cayami1,8, Wessel N van Wieringen9, Petra J W Pouwels10,11, Marjo S van der Knaap1,11,12, Geneviève Bernard3,13,14, Nicole I Wolf1,11.   

Abstract

4H (hypomyelination, hypodontia and hypogonadotropic hypogonadism) leukodystrophy (4H) is an autosomal recessive hypomyelinating white matter (WM) disorder with neurologic, dental, and endocrine abnormalities. The aim of this study was to develop and validate a magnetic resonance imaging (MRI) scoring system for 4H. A scoring system (0-54) was developed to quantify hypomyelination and atrophy of different brain regions. Pons diameter and bicaudate ratio were included as measures of cerebral and brainstem atrophy, and reference values were determined using controls. Five independent raters completed the scoring system in 40 brain MRI scans collected from 36 patients with genetically proven 4H. Interrater reliability (IRR) and correlations between MRI scores, age, gross motor function, gender, and mutated gene were assessed. IRR for total MRI severity was found to be excellent (intraclass correlation coefficient: 0.87; 95% confidence interval: 0.80-0.92) but varied between different items with some (e.g., myelination of the cerebellar WM) showing poor IRR. Atrophy increased with age in contrast to hypomyelination scores. MRI scores (global, hypomyelination, and atrophy scores) significantly correlated with clinical handicap (p < 0.01 for all three items) and differed between the different genotypes. Our 4H MRI scoring system reliably quantifies hypomyelination and atrophy in patients with 4H, and MRI scores reflect clinical disease severity. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2017        PMID: 28561206     DOI: 10.1055/s-0037-1599141

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  8 in total

1.  Treacher Collins syndrome mutations in Saccharomyces cerevisiae destabilize RNA polymerase I and III complex integrity.

Authors:  Nancy Walker-Kopp; Ashleigh J Jackobel; Gianno N Pannafino; Paola A Morocho; Xia Xu; Bruce A Knutson
Journal:  Hum Mol Genet       Date:  2017-11-01       Impact factor: 6.150

2.  Expanding the phenotypic and molecular spectrum of RNA polymerase III-related leukodystrophy.

Authors:  Stefanie Perrier; Laurence Gauquelin; Catherine Fallet-Bianco; Megan K Dishop; Mackenzie A Michell-Robinson; Luan T Tran; Kether Guerrero; Lama Darbelli; Myriam Srour; Kevin Petrecca; Deborah L Renaud; Michael Saito; Seth Cohen; Steffen Leiz; Bader Alhaddad; Tobias B Haack; Ingrid Tejera-Martin; Fernando I Monton; Norberto Rodriguez-Espinosa; Daniela Pohl; Savithri Nageswaran; Annette Grefe; Emma Glamuzina; Geneviève Bernard
Journal:  Neurol Genet       Date:  2020-05-11

3.  A novel POLR3A genotype leads to leukodystrophy type-7 in two siblings with unusually late age of onset.

Authors:  Rosa Campopiano; Rosangela Ferese; Stefania Zampatti; Emiliano Giardina; Francesca Biagioni; Claudio Colonnese; Diego Centonze; Marianna Storto; Fabio Buttari; Edoardo Fraviga; Vania Broccoli; Mirco Fanelli; Francesco Fornai; Stefano Gambardella
Journal:  BMC Neurol       Date:  2020-06-29       Impact factor: 2.474

4.  Biallelic POLR3A variants confirmed as a frequent cause of hereditary ataxia and spastic paraparesis.

Authors:  Siri L Rydning; Jeanette Koht; Ying Sheng; Piotr Sowa; Hanne S Hjorthaug; Iselin M Wedding; Anne Kjersti Erichsen; Inger Anette Hovden; Paul H Backe; Chantal M E Tallaksen; Magnus D Vigeland; Kaja K Selmer
Journal:  Brain       Date:  2019-04-01       Impact factor: 13.501

5.  POLR3-Related Leukodystrophy: Exploring Potential Therapeutic Approaches.

Authors:  Stefanie Perrier; Mackenzie A Michell-Robinson; Geneviève Bernard
Journal:  Front Cell Neurosci       Date:  2021-01-28       Impact factor: 5.505

6.  Genome sequencing identifies three molecular diagnoses including a mosaic variant in the COL2A1 gene in an individual with Pol III-related leukodystrophy and Feingold syndrome.

Authors:  Kayla J Muirhead; Amanda R Clause; Zinayida Schlachetzki; Holly Dubbs; Denise L Perry; R Tanner Hagelstrom; Ryan J Taft; Adeline Vanderver
Journal:  Cold Spring Harb Mol Case Stud       Date:  2021-12-09

7.  POLR3A variants with striatal involvement and extrapyramidal movement disorder.

Authors:  Inga Harting; Murtadha Al-Saady; Ingeborg Krägeloh-Mann; Annette Bley; Maja Hempel; Tatjana Bierhals; Stephanie Karch; Ute Moog; Geneviève Bernard; Richard Huntsman; Rosalina M L van Spaendonk; Maaike Vreeburg; Agustí Rodríguez-Palmero; Aurora Pujol; Marjo S van der Knaap; Petra J W Pouwels; Nicole I Wolf
Journal:  Neurogenetics       Date:  2020-01-15       Impact factor: 2.660

8.  Endocrine and Growth Abnormalities in 4H Leukodystrophy Caused by Variants in POLR3A, POLR3B, and POLR1C.

Authors:  Félixe Pelletier; Stefanie Perrier; Ferdy K Cayami; Amytice Mirchi; Stephan Saikali; Luan T Tran; Nicole Ulrick; Kether Guerrero; Emmanouil Rampakakis; Rosalina M L van Spaendonk; Sakkubai Naidu; Daniela Pohl; William T Gibson; Michelle Demos; Cyril Goizet; Ingrid Tejera-Martin; Ana Potic; Brent L Fogel; Bernard Brais; Michel Sylvain; Guillaume Sébire; Charles Marques Lourenço; Joshua L Bonkowsky; Coriene Catsman-Berrevoets; Pedro S Pinto; Sandya Tirupathi; Petter Strømme; Ton de Grauw; Dorota Gieruszczak-Bialek; Ingeborg Krägeloh-Mann; Hanna Mierzewska; Heike Philippi; Julia Rankin; Tahir Atik; Brenda Banwell; William S Benko; Astrid Blaschek; Annette Bley; Eugen Boltshauser; Drago Bratkovic; Klara Brozova; Icíar Cimas; Christopher Clough; Bernard Corenblum; Argirios Dinopoulos; Gail Dolan; Flavio Faletra; Raymond Fernandez; Janice Fletcher; Maria Eugenia Garcia Garcia; Paolo Gasparini; Janina Gburek-Augustat; Dolores Gonzalez Moron; Aline Hamati; Inga Harting; Christoph Hertzberg; Alan Hill; Grace M Hobson; A Micheil Innes; Marcelo Kauffman; Susan M Kirwin; Gerhard Kluger; Petra Kolditz; Urania Kotzaeridou; Roberta La Piana; Eriskay Liston; William McClintock; Meriel McEntagart; Fiona McKenzie; Serge Melançon; Anjum Misbahuddin; Mohnish Suri; Fernando I Monton; Sebastien Moutton; Raymond P J Murphy; Miriam Nickel; Hüseyin Onay; Simona Orcesi; Ferda Özkınay; Steffi Patzer; Helio Pedro; Sandra Pekic; Mercedes Pineda Marfa; Amy Pizzino; Barbara Plecko; Bwee Tien Poll-The; Vera Popovic; Dietz Rating; Marie-France Rioux; Norberto Rodriguez Espinosa; Anne Ronan; John R Ostergaard; Elsa Rossignol; Rocio Sanchez-Carpintero; Anna Schossig; Nesrin Senbil; Laura K Sønderberg Roos; Cathy A Stevens; Matthis Synofzik; László Sztriha; Daniel Tibussek; Dagmar Timmann; Davide Tonduti; Bart P van de Warrenburg; Maria Vázquez-López; Sunita Venkateswaran; Pontus Wasling; Evangeline Wassmer; Richard I Webster; Gert Wiegand; Grace Yoon; Joost Rotteveel; Raphael Schiffmann; Marjo S van der Knaap; Adeline Vanderver; Gabriel Á Martos-Moreno; Constantin Polychronakos; Nicole I Wolf; Geneviève Bernard
Journal:  J Clin Endocrinol Metab       Date:  2021-01-23       Impact factor: 5.958

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.